营收:Q4营收从去年同期的1370万美元下降至980万美元,2017财年营收为2250万美元,同比下降36.6%。
运营成本:第四季度的运营成本同比上升2680万美元,至9570万美元。整财年运营成本下降990万美元,至2.952亿。其中,Q4研发成本同比...查看全文
淘沙见金2018-03-01 07:35
$Portola制药(PTLA)$ 直觉上来说FDA要求应该是批准后的额外临床试验,否则这个问题不应该之前的CRL都不提的。理想的状态是A药五月份批准+post market trial,那今天这30的股价就是来送礼的。不理想的状态就是A药五月份CRL+额外两年时间做临床(股价20见)。这么重大的消息管理层居然不放在新闻稿,...查看全文
$Portola制药(PTLA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-040371 Size: 12 KB 网页链接
$Portola制药(PTLA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-040380 Size: 16 KB 网页链接
$Portola制药(PTLA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-040346 Size: 20 KB 网页链接
$Portola制药(PTLA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-040356 Size: 8 KB 网页链接
$Portola制药(PTLA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-040364 Size: 13 KB 网页链接
$Portola制药(PTLA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-040326 Size: 23 KB 网页链接
$Portola制药(PTLA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-040332 Size: 10 KB 网页链接
$Portola制药(PTLA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-040341 Size: 25 KB 网页链接
$Portola制药(PTLA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-040307 Size: 23 KB 网页链接
$Portola制药(PTLA)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001209191-20-040311 Size: 12 KB 网页链接